Neuphoria Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Name: Neuphoria Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Neuphoria Therapeutics Inc.
Rating: 2.89125
Author: Trendlyne DVM scores

about

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral...

8.16 -0.40 (-4.67%)

34.98% Fall from 52W High

48,540

XNAS Volume

XNAS 30 Jul, 2025 5:30 PM (EDT)

Not Eligible

Mid Valuation

43.5 / 100

Technically Bullish

72.2 / 100

No estimates available

Neuphoria Therapeutics Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neuphoria Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral...

34.98% Fall from 52W High

SWOT Analysis

Neuphoria Therapeutics Inc. Live Price Chart